GlassScriptPhysician profile
John Mathew Gowans
NPI 1093001208
$437.25
in general payments reported to CMS, 2019-2025
11 companies · $34.68 in 2025
The $34.68 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $61.54 · 2021: $51.31 · 2022: $119 · 2024: $47.92 · 2025: $34.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $94.69 | 2022 | |
| Boston Scientific Corporation | $80.98 | 2019 | |
| Amgen INC. | $72.04 | 2019-2021 | |
| Abbott Laboratories | $61.04 | 2021-2022 | |
| Livanova USA, INC. | $26.84 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Medtronic, INC. | $21.08 | 2024 | Osteocool Rf Ablation System |
| Lundbeck LLC | $20.64 | 2025 | Rexulti |
| Pfizer INC. | $16.04 | 2020 | |
| Amarin Pharma, INC. | $15.08 | 2019 | |
| Medtronic USA, INC. | $14.78 | 2020 | |
| Novo Nordisk INC | $14.04 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gowans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.